Supreme Cannabis Shows its Brand Value with the Tilray Agreement

The Supreme Cannabis Company, Inc. (TSXV:FIRE), one of the Canadian marijuana stocks, announced a supply agreement with Tilray Inc. (NASDAQ:TLRY) valued at approximately C$12 million

SmallCapPower | October 4, 2018: The Supreme Cannabis Company, Inc. (TSXV:FIRE), one of the Canadian cannabis stocks, announced recently that the Company’s wholly-owned subsidiary, 7ACRES, has entered into a guaranteed supply agreement to provide dried cannabis to Tilray Canada Ltd., a subsidiary of Tilray Inc. (NASDAQ:TLRY). The contract value is estimated to be ~C$12 million for a 12-month period starting October 1, 2018.

Supreme Cannabis President John Fowler said, “We are excited to be entering into this agreement with Tilray, an organization – like Supreme Cannabis – that focuses on the end user and demands leading quality assurance standards. Tilray has built an industry-leading global medical distribution platform, which has resulted in robust demand for high quality cannabis products. We are happy to provide 7ACRES premium products alongside Tilray’s well-regarded and existing lineup to support medical patients around the world.”

Win Big With Our Small Cap Picks

Leave this field empty if you're human:

Tilray is a leading cannabis company specializing in medical research, cultivation, processing and distribution. It is a GMP-certified medical cannabis producer supplying cannabis flower and extract products to several patients, physicians, pharmacies, hospitals, governments and researchers across the globe. It cultivates a wide range of strains to meet patient needs including indicas, sativas, hybrids, and CBD-rich varieties.

Supreme Cannabis also posted recently record Q4 2018 sales of $3.55 million, a 71% quarter-over-quarter increase, while its fiscal year 2018 revenue came in at $8.85 million. Supreme Cannabis has signed several wholesale supply agreements with companies such as Aurora Cannabis Inc. (TSX:ACB) and Namaste Technologies Inc. (TSXV:N).

In addition, on September 27, 2018, Supreme Cannabis announced a $90 million bought-deal financing of convertible debentures.

Supreme Cannabis Company stock trades at a market capitalization of C$564.83 million with a price-to-book ratio of 3.8x, whereas Tilray Inc has a market capitalization of $14.6 billion with a price-to-book ratio of 333.7x.

Disclosure: Neither the author nor his family own shares in any of the companies mentioned above.

To read our full disclosure, please click on the button below:

The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. The Reader should apply his/her own judgment in making any use of any Content, including, without limitation, the use of any information contained therein as the basis for any conclusions. The Reader bears responsibility for his/her own investment research and decisions. Before making any investment decision, it is strongly recommended that you seek outside advice from a qualified investment advisor. SmallCapPower/Ubika Research does not provide or guarantee any financial, legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or information source. Ubika and/or its affiliates and/or their respective officers, directors or employees may from time to time acquire, hold or sell securities and/or commodities and/or commodity futures contracts in certain underlying companies mentioned in this site and which may also be clients of Ubika’s affiliates. In such instances, Ubika and/or its affiliates and/or their respective officers, directors or employees will use all reasonable efforts to avoid engaging in activities that would lead to conflicts of interest and Ubika and/or its affiliates will use all reasonable efforts to comply with conflicts of interest disclosures and regulations to minimize the conflict.